Wednesday, October 02, 2013 1:45:59 PM
Regenerative medicine company, AxoGen, was recently featured in a Seeking Alpha article in which author Equity Options Guru wrote a continuation of a previous write-up discussing the company’s strong upside based on five key points. To read the article in its entirety, visit http://seekingalpha.com/article/1724602.
AxoGen is focused on peripheral nerve reconstruction and regeneration with an overarching goal to provide treatment for patients suffering from traumatic injuries or who are undergoing surgeries that impact the function of peripheral nerves. The company’s pipeline includes Advance Nerve Graft – the company’s alternative to autografts; AxoGuard Nerve Protector – used to reinforce a coaptation site, wrap a partially severed or compressed nerve, isolate tissue; and the AxoGuard Nerve Connector – a coaptation aid for close approximation of severed nerve ends.
“The target market for these products is the medical community, specifically surgeons. The above technologies can provide a way for surgeons to reconstruct injured nerves without the comorbidities associated with a secondary surgical site,” wrote Equities Options Guru in detailing the company’s technology. “As such, the market potential is immense.”
Further into his positive review of AxoGen, Equity Options Guru details the company’s diverse pipeline of products and technologies, the stock’s recent uplisting to the NASDAQ exchange, significant insider buying, recent coverage by analysts at JMP Securities, and the company’s strong cash balance and revenue growth.
Among other key points, the author also noted that there are two large institutional holders of AxoGen shares, and highlights JMP Securities Outperform rating and $7 price target on the company’s stock, along with reporting information from a recent research note.
In conclusion, Equity Options Guru opines his bullish take on the company.
“Based on the 5 reasons above, it appears that AxoGen is headed for a bright future. With the recent insider buying and positive analyst coverage, investors should begin to take notice of this significantly undervalued company. And with the recent improvement in the company’s financials, AxoGen should begin to gain more traction in the nerve repair market and help investors reap the rewards of an early investment,” stated Equity Options Guru.
For more information visit on AxoGen visit: www.AxoGenInc.com
Recent AXGN News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/17/2024 08:14:15 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/13/2024 08:30:37 PM
- Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] • Edgar (US Regulatory) • 09/10/2024 08:00:03 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/06/2024 11:09:28 AM
- Axogen Completes Submission of Biologics License Application to U.S. Food and Drug Administration for Avance Nerve Graft® • GlobeNewswire Inc. • 09/06/2024 11:00:00 AM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 09/05/2024 08:33:06 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/05/2024 01:13:28 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/05/2024 01:11:56 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/05/2024 12:58:50 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/05/2024 12:52:34 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/04/2024 11:52:19 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/04/2024 09:18:07 PM
- Axogen Reports Inducement Grant to New Employee Under NASDAQ Listing Rule 5635(C)(4) • GlobeNewswire Inc. • 09/03/2024 11:00:00 AM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 08/21/2024 08:31:56 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 08/13/2024 09:00:23 PM
- CytoSorbents Appoints Peter J. Mariani Chief Financial Officer • GlobeNewswire Inc. • 08/13/2024 08:18:28 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 08/12/2024 02:59:34 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 08/09/2024 08:36:36 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/09/2024 08:20:03 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 08/09/2024 08:15:02 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/09/2024 08:05:37 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/08/2024 08:10:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/08/2024 11:14:47 AM
- Axogen, Inc. Announces New Leadership Appointments • GlobeNewswire Inc. • 08/08/2024 11:05:00 AM
- Axogen, Inc. Reports Second Quarter 2024 Financial Results • GlobeNewswire Inc. • 08/08/2024 11:00:00 AM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM